EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Augmentation Therapy With Serotonin 5‐ HT 1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies

Risa Yamada iD, Ayumu Wada, Andrew Stickley iD, Adrian Newman-Tancredi iD, Tomiki Sumiyoshi iD

Neuropsychopharmacology Reports · 2025-06 · 45 (2)

DOI: 10.1002/npr2.70023 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 27.05.2025. Verfasst von Risa Yamada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, To…. Hauptthemen laut MEDLINE: Serotonin 5-HT1 Receptor Agonists, Cognition, Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Intramural Research Grants for Neurological and Psychiatric Disorders, Psychiatry, and Japan Health Research Promotion Bureau Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The use of serotonin 5‐HT 1A receptor partial agonists (5‐HT 1A ‐PAs) as an add‐on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5‐HT 1A receptors have been shown to play a role in the pathophysiology of mood disorders. There is compelling evidence supporting that stimulation of 5‐HT 1A receptors accelerates antidepressant effects. Accordingly, this systematic review examines the ability of adjunctive treatment with 5‐HT 1A ‐PAs to improve cognitive function in patients with depressive symptoms.

Methods

A literature search using PubMed, the Cochrane Library, and Web of Science databases was performed from 1987 to January 2024 to identify randomized controlled trials (RCTs) corresponding to the following inclusion criteria: (1) RCTs, (2) human studies; studies that (3) targeted patients with a psychiatric disorder (except for schizophrenia or schizoaffective disorder), (4) evaluated the effect of cognitive functions, (5) were written in English.

Results

From the 80 studies initially screened, three met the inclusion criteria. Two of these studies dealt with vascular depression while one focused on major depressive disorder (MDD). In MDD, combined treatment with buspirone and melatonin was more efficacious in ameliorating subjective cognitive disturbances compared to the use of buspirone alone or the use of a placebo. Likewise, the combination of escitalopram–tandospirone was more advantageous than escitalopram alone for improving executive function and verbal fluency in patients with vascular depression.

Conclusions

Further studies with novel 5‐HT 1A receptor agonists are warranted to examine their potentially more robust benefits on cognitive performance in subjects suffering from mood deficits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serotonin 5-HT1 Receptor AgonistsCognitionMajor Depressive DisorderAntidepressive AgentsHumansRandomized Controlled Trials as TopicDrug Therapy, Combination

Stichwörter der Autor:innen

5‐HT1A receptor biased agonists5‐HT1A receptor partial agonistsazapirone derivativecognitive impairmentdepression

Substanzen

Serotonin 5-HT1 Receptor AgonistsAntidepressive Agents

Autor:innen und Institutionen

  • Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Department of Psychiatry, National Center Hospital of Neurology and Psychiatry, Tokyo, Japan.
  • Neurolixis, Castres, France.

ORCID-Profile: Risa Yamada, Andrew Stickley, Adrian Newman-Tancredi, Tomiki Sumiyoshi

Förderung

  • Japan Society for the Promotion of Science
  • Intramural Research Grants for Neurological and Psychiatric Disorders
  • Psychiatry, and Japan Health Research Promotion Bureau Grants
  • AMED Grant

Zitieren

APA

Yamada, R., Wada, A., Stickley, A., Newman-Tancredi, A., & Sumiyoshi, T. (2025). Augmentation Therapy With Serotonin 5‐ HT 1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies. Neuropsychopharmacology Reports, 45(2). https://doi.org/10.1002/npr2.70023

Vancouver

Yamada R, Wada A, Stickley A, Newman-Tancredi A, Sumiyoshi T. Augmentation Therapy With Serotonin 5‐ HT 1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies. Neuropsychopharmacology Reports. 2025;45(2). doi:10.1002/npr2.70023

BibTeX
@article{Yamada2025,
  author = {Yamada, Risa and Wada, Ayumu and Stickley, Andrew and Newman-Tancredi, Adrian and Sumiyoshi, Tomiki},
  title = {Augmentation Therapy With Serotonin 5‐ HT 1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies},
  journal = {Neuropsychopharmacology Reports},
  year = {2025},
  volume = {45},
  number = {2},
  doi = {10.1002/npr2.70023}
}
Kostenlos starten →